ARCH Venture Fund VII, L.P.
CIK 1402439 · last filed 2020-12-22
ARCH Venture Fund VII, L.P. is a corporate insider who has filed 4 SEC Form 4 insider transactions across 4 companies since 2013. The most recent filing, for MASS, was dated Dec 22, 2020. Across all open-market trades the lifetime net is +$58.5M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $66.7M across reported positions. The firm reports its address in Chicago, IL. 39 SEC filings were submitted jointly with ARCH Venture Partners VII, L.P.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MASS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 1025
Chicago, IL 60631
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MASS | 10%+ Owner | 5,725,045 | $11.65 | $66.70M | $30.00M | 1 | 2020-12-22 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | 10%+ Owner | 463,714 | $0.00 | $185 | $25.00M | 1 | 2016-07-07 |
| PULM | 10%+ Owner | 11,069 | $1.44 | $15.9K | $3.50M | 1 | 2015-06-17 |
| bluebird bio, Inc. (BLUE) Delisted | 10%+ Owner | 89,679 | $4.97 | $445.7K | $0 | 1 | 2013-06-26 |
Recent Filings
4 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-12-22 | MASS | Mixed | +28,625,225 | $30.00M | EDGAR |
| 2016-07-07 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Mixed | +22,119,020 | $25.00M | EDGAR |
| 2015-06-17 | PULM | Mixed | +16,005,192 | $3.50M | EDGAR |
| 2013-06-26 | bluebird bio, Inc. (BLUE) Delisted | Conv (C) | +10,761,528 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.